RKLY - RKLY STOCK NEWS

Rockley Photonics (NYSE: RKLY), based in Oxford and Pasadena, announces it will not proceed with the technical sale of its data-communications technology to Hengtong Rockley Technology due to its partner being placed on the U.S. Entity List. This decision has prompted the company to revise its revenue outlook for 2021 and 2022, targeting $7-$8 million and $25-$30 million, respectively. Despite this setback, Rockley remains committed to its primary business in health monitoring and believes the change will ultimately benefit long-term growth.

Rockley Photonics (NYSE: RKLY) has announced successful preliminary human studies for its non-invasive biomarker sensing platform, specifically in measuring core body temperature. The platform utilizes photonics-based sensors for improved accuracy compared to traditional thermometers. This innovation allows for continuous temperature monitoring via wearables, potentially aiding early disease detection. Dr. Andrew Rickman, CEO, emphasized the platform's capacity to support various biomarker measurements and enhance digital health analytics.

Rockley Photonics has partnered with the Icahn School of Medicine at Mount Sinai to explore applications for its non-invasive biomarker sensing platform in clinical research. The collaboration aims to evaluate the use of wearables for remote health monitoring and diagnosis. Rockley's patented photonics technology broadens the range of detectable biomarkers, including core body temperature and glucose levels, enhancing its potential for transforming digital healthcare. This initiative could lead to significant advancements in real-time health insights.

Rockley Photonics Holdings Limited (NYSE: RKLY) reported revenue of $1.8 million for Q3 2021, down from $2.2 million in Q2. The company has a backlog of $23.0 million and completed its business combination with SC Health. Major partnerships were signed with top consumer electronics and medtech firms, enhancing its VitalSpex™ biomarker sensing platform. However, Rockley recorded a GAAP net loss of $58.0 million and cash used in operations increased to $37.4 million. The company maintains $125.0 million in cash and investments as of September 30, 2021.

Rockley Photonics (NYSE: RKLY) has signed partnership agreements with five top global consumer electronics manufacturers to enhance its non-invasive VitalSpex™ biomarker sensing platform. These collaborations will enable the integration of advanced biomarker measurements into consumer devices like smartwatches and wristbands, expanding Rockley's market presence. The platform aims to deliver real-time health insights by measuring various biomarkers including body temperature, blood pressure, and glucose trends. Rockley is conducting human studies to refine its sensing technology.

Rockley Photonics (NYSE: RKLY) announced a new research collaboration with Caltech’s Sensing to Intelligence (S2I) Center to develop advanced sensor systems integrated with artificial intelligence. This partnership aims to enhance health monitoring capabilities by merging sensing and computational disciplines. Rockley plans to invest in projects that will advance integrated spectrometer technologies using photonic sensors. The collaboration, building on a strong prior relationship, is expected to leverage existing expertise and explore applications for cloud-based services with platforms like Amazon Web Services.

Rockley Photonics (NYSE: RKLY) will report its Q3 fiscal year 2021 financial results on November 15, 2021, after market close. The company will hold a conference call at 5:00 p.m. ET to discuss these results and the business outlook. Interested participants can access the call via phone or through a live webcast on Rockley’s investor relations page. A replay will be available until November 29, 2021.

Rockley Photonics (NYSE: RKLY) has announced strategic partnerships with two major medical equipment manufacturers, enhancing its non-invasive biomarker sensing technology. The partnerships aim to expand applications in health monitoring and early disease detection across various medical devices used in clinics and hospitals. With over $40 billion in combined revenue, these partnerships are expected to facilitate the integration of Rockley’s innovative technology into consumer and medical technologies, pushing forward digital healthcare.

Rockley Photonics Holdings Limited (NYSE: RKLY) will participate in Deutsche Bank's 2021 Technology Conference on September 9, 2021, at 8:30 a.m. ET. The company, a leader in silicon photonics technology, offers innovative solutions for mobile health monitoring and data communications. Live webcasts of the presentations will be available on the Rockley investor relations page. Rockley aims to revolutionize industries with its comprehensive range of photonic integrated circuits, targeting mass markets and various vertical applications.